An interventional study of the pregnancy rate at IVF / ICSI cycles in PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, sponsored by Egymedicalpedia. Recruiting at 1 site in Egypt. Open to female participants aged 20 Years to 35 Years. Per ClinicalTrials.gov, last updated 2023-10-19.
Sponsored by Egymedicalpedia · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Polycystic Ovary Syndrome with a site in Egypt — 16 open to participants now, 18 under way, 1 of them phase 3. Polycystic Ovary Syndrome · Egypt.
Among the 104 studies in Polycystic Ovary Syndrome with a site in Egypt, this one is the 24th largest by planned enrollment of the 83 interventional ones that give a count, is one of 12 that started in 2023, is one of 44 with no phase, reaches primary completion later than 12 of the 17 other live ones, and was the 59th registered.
958 studies on the registry are indexed under Polycystic Ovary Syndrome; 175 are open to participants now.
Browse Polycystic Ovary Syndrome studies →16 of the 104 studies in Polycystic Ovary Syndrome with a site in Egypt are open now. Recruiting first, the newest first:
Adly A Adam · Sites in Egypt
Ages 25–35 · Women only
Cairo University · Sites in Egypt
Ages 20–40 · Women only
Cairo University · Sites in Egypt
Ages 20–30 · Women only
Cairo University · Sites in Egypt
Ages 30–40 · Women only
Cairo University · Sites in Egypt
Ages 35–45 · Women only
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 20 Years to 35 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 10 · Phase 3 12 · Phase 4 13
First in 2005; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 156 is above the median of 70 across 699 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 100 across the 83 interventional studies, 100 across the 21 observational. Of the 64 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 104 have an industry lead sponsor. The 10 most frequent:
Egymedicalpedia is the lead sponsor of 58 studies on the registry; 13 are open to participants now.
Egymedicalpedia has 3 studies filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
6 of the studies in Polycystic Ovary Syndrome with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05756023EgymedicalpediaIVF\ICSI Outcome in Women With Polycystic Ovary Syndrome | 2026-12-01 |
| NCT07871175British University In EgyptInspiratory Muscle Training for the Management of Polyendocrine Metabolic Ovarian Syndrome | 2026-12-02 |
| NCT07604779Beni-Suef UniversityEnhancing PCOS Management for Better Outcomes of Intracytoplasmic Sperm Injection | 2026-12-03 |
| NCT07591246Cairo UniversityEfficay of Physical Activity Program in PCOS Females With Fatty Pancrease and Thyroid Hypofunction | 2026-12-30 |
| NCT07708766Cairo UniversityEffect of High Intensity Interval Training on Insulin Resistance in Polycystic Ovarian Syndrome | 2027-01-15 |
Add all 6 to your calendar (.ics) → With an account.
Among the 104 studies in Polycystic Ovary Syndrome with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Polycystic ovarian syndrome (PCOS) occurs in 5% to 10% of all women of reproductive age and 50% of women who present with sub-fertility due to anovulatory infertility . Clear diagnostic criteria for this condition were identified at the consensus meeting of the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine .
Sub-fertile women with PCOS will usually benefit from conventional treatments, such as lifestyle changes, ovulation induction, or laparoscopic ovarian drilling, but some will ultimately need assisted reproductive techniques, either if they will need or if they wish, such as controlled ovarian hyperstimulation and IVF.
In these cases, controlled ovarian hyperstimulation is closely related to high drug costs, need for daily injections and frequent monitoring, whereas it sometimes results in an increased rate of cycle cancellations and potential life threatening complications due to ovarian hyperstimulation syndrome and in the retrieval of immature oocytes, leading to poor fertilization and lower cleavage, pregnancy, and live birth rates compared to the conventional IVF cycles ,although this has not been confirmed by other studies .
In addition, ovulation induction is associated with a high risk of multiple pregnancies due to multiple follicular development, so that it has to be individualized and closely monitored.
In-vitro fertilization (IVF) is a common therapeutic modality used in infertile women. IVF has different success rates in different subgroups of patients.
It is necessary to alter the common standard protocols to overcome the potential obstacles in some populations of patients and achieve the best results . Obesity with PCOS status of patient may decrease the fertilization rate and clinical pregnancy chance after IVF (probably by decreasing the oocyte count and increasing the gonadotropin resistance); however, the results of different studies are conflicting
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To compare the pregnancy rate at IVF / ICSI cycles in patients with PCOs
Procedure: the pregnancy rate at IVF / ICSI cycles
To compare the pregnancy rate at IVF / ICSI cycles in patients with without PCOs
Procedure: the pregnancy rate at IVF / ICSI cycles
To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS
pregnancy rate
To compare the pregnancy rate at IVF / ICSI cycles between women with PCOS and non PCOS women
Time frame: From baseline to 15 days after the embryo transfere day.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.
Of 219 interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 42 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.